These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 29924966)
1. A Proteomic Variant Approach (ProVarA) for Personalized Medicine of Inherited and Somatic Disease. Hutt DM; Loguercio S; Campos AR; Balch WE J Mol Biol; 2018 Sep; 430(18 Pt A):2951-2973. PubMed ID: 29924966 [TBL] [Abstract][Full Text] [Related]
2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Southern KW; Murphy J; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662 [TBL] [Abstract][Full Text] [Related]
3. Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence. Kotha K; Clancy JP Ther Adv Respir Dis; 2013 Oct; 7(5):288-96. PubMed ID: 24004658 [TBL] [Abstract][Full Text] [Related]
4. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
6. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. Januska MN; Marx L; Walker PA; Berdella MN; Langfelder-Schwind E J Genet Couns; 2020 Aug; 29(4):607-615. PubMed ID: 32227567 [TBL] [Abstract][Full Text] [Related]
7. Cystic fibrosis: a model system for precision medicine. Martiniano SL; Sagel SD; Zemanick ET Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658 [TBL] [Abstract][Full Text] [Related]
8. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis. Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539 [TBL] [Abstract][Full Text] [Related]
9. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation. Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700 [TBL] [Abstract][Full Text] [Related]
10. Sweat Proteomics in Cystic Fibrosis: Discovering Companion Biomarkers for Precision Medicine and Therapeutic Development. Burat B; Reynaerts A; Baiwir D; Fléron M; Gohy S; Eppe G; Leal T; Mazzucchelli G Cells; 2022 Jul; 11(15):. PubMed ID: 35954202 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function. Arora K; Naren AP Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081 [TBL] [Abstract][Full Text] [Related]
12. A small molecule CFTR potentiator restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR. Liu J; Berg AP; Wang Y; Jantarajit W; Sutcliffe KJ; Stevens EB; Cao L; Pregel MJ; Sheppard DN Br J Pharmacol; 2022 Apr; 179(7):1319-1337. PubMed ID: 34644413 [TBL] [Abstract][Full Text] [Related]
13. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. Amico G; Brandas C; Moran O; Baroni D Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989 [TBL] [Abstract][Full Text] [Related]
16. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
17. Association of IVS6A GATT polymorphism of CFTR gene with cystic fibrosis: first study in CF and normal Tunisian population. Chaima S; Sondess HF; Khedija B; Ahmed M; Taieb M Ann Biol Clin (Paris); 2020 Jun; 78(3):314-318. PubMed ID: 32540817 [TBL] [Abstract][Full Text] [Related]
18. Translating the genetics of cystic fibrosis to personalized medicine. Corvol H; Thompson KE; Tabary O; le Rouzic P; Guillot L Transl Res; 2016 Feb; 168():40-49. PubMed ID: 25940043 [TBL] [Abstract][Full Text] [Related]
19. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back. Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881 [TBL] [Abstract][Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]